Daciana Costina Andrada Dunca - Stefan

Dr. Daciana Costina Andrada Dunca - Stefan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MDMaria-Zinaida Dobre
Maria-Zinaida Dobre
BVBogdana Virgolici
Bogdana Virgolici
DSDaciana Costina Andrada Dunca - Stefan
Daciana Costina Andrada Dunca - Stefan
IDIoana Cristina Doicin
Ioana Cristina Doicin
Iulia-Ioana Stanescu-SpinuIulia-Ioana Stanescu-Spinu
Iulia-Ioana Stanescu-Spinu
Insulin resistance develops when skeletal muscle (SM), adipose tissue (AT), and the liver fail to respond adequately to insulin, a dysfunction closely intertwined with chronic low-grade inflammation. This combination leads to compensatory hyperinsulinemia, dysglycemia, and metabolic stress, driving major disorders such as type 2 diabetes, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular disease. Both adipokines and myokines are central modulators of this metabolic–inflammatory axis. In obesity, diabetes, MASLD, and thyroid dysfunction, alterations in myokines such as myostatin, irisin, fibroblast growth factor 21 (FGF-21), apelin, brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), and interleukin-15 (IL-15) influence glucose uptake, lipid oxidation, mitochondrial function, and systemic inflammation. Exercise-induced myokines exert insulin-sensitizing and anti-inflammatory effects, whereas myostatin and tumor necrosis factor-alpha (TNF-α) promote metabolic impairment. These pathways reveal extensive crosstalk between SM and key metabolic organs—including the liver, pancreas, AT, intestine, heart, and thyroid gland. In metabolic disease, inflammation-driven changes in deiodinase activity and triiodothyronine (T3) availability further link muscle dysfunction with thyroid imbalance. The aim of this narrative review was to elucidate the complex interplay between myokines, adipokines, inflammation, and insulin resistance, and to clarify their clinical relevance in metabolic and thyroid disorders. Given this integrative role of SM, sarcopenia should be recognized as a clinical marker of metabolic or thyroid dysregulation, and preserving muscle mass through structured physical activity should be a core therapeutic target.

Verified
Journal Article
Open access
PDF file
BVBogdana Virgolici
Bogdana Virgolici
MDMaria-Zinaida Dobre
Maria-Zinaida Dobre
DSDaciana Costina Andrada Dunca - Stefan
Daciana Costina Andrada Dunca - Stefan
Obesity causes fat accumulation, and sarcopenia causes loss of muscle mass and strength; together, they worsen insulin resistance and accelerate muscle decline, creating a harmful cycle. Some supplements, along with physical exercise, could be remedies for sarcopenic obesity (SO). In this review, we aim to draw a comparison between supplements studied in experimental research and those evaluated in clinical studies for SO. In experimental studies, Sea Buckthorn—in forms such as oil, freeze-dried powder or pomace—has been shown to enhance muscle cell growth, improve gut microbiota, provide hypoglycemic benefits and increase muscle mass by promoting protein synthesis. Increased consumption of Omega-3 fatty acids may play a protective role against SO in women. Melatonin may positively impact obesity and SO by reducing oxidative stress. Elevated irisin levels, such as those observed with vitamin D supplementation, could prevent muscle wasting and fat gain in SO by improving insulin sensitivity and reducing inflammation. There have been many studies highlighting the potential of vitamin D in preventing age related sarcopenia; however, the effect of vitamin D supplementation in SO is under-researched and appears less promising. Future clinical trials using natural supplements hold promise, as these provide multiple beneficial components that may work synergistically to treat SO.

4 March 2025
Verified
Book Chapter
Open access
PDF file
MDMaria-Zinaida Dobre
Maria-Zinaida Dobre
BVBogdana Virgolici
Bogdana Virgolici
DSDaciana Costina Andrada Dunca - Stefan
Daciana Costina Andrada Dunca - Stefan
ATAndreea-Consuela Timnea-Florescu
Andreea-Consuela Timnea-Florescu
OTOlivia Carmen Timnea
Olivia Carmen Timnea
Sea buckthorn (SB) offers remarkable health benefits through the synergistic actions of its bioactive compounds. High levels of vitamin C, carotenoids and flavonoids enhance neurogenesis, reduce neuroinflammation and support collagen synthesis. This synergy extends to gut health, fostering beneficial bacteria and reducing oxidative stress. SB’s balanced profile of essential fatty acids further amplifies the bioavailability and effectiveness of fat-soluble vitamins. Omega-7, for example, works in concert with vitamin E to promote skin regeneration and reduce oxidative damage, while omega-3 and omega-6 modulate inflammatory responses and enhance the antioxidant functions of vitamins A and E. Rich in antioxidants like polyphenols and lycopene, SB combats oxidative damage and supports cardiovascular health, solidifying its status as a functional superfood.

16 February 2026
Verified
Book Chapter
Open access
PDF file
MDMaria-Zinaida Dobre
Maria-Zinaida Dobre
BVBogdana Virgolici
Bogdana Virgolici
ATAndreea-Consuela Timnea-Florescu
Andreea-Consuela Timnea-Florescu
OTOlivia Carmen Timnea
Olivia Carmen Timnea
DSDaciana Costina Andrada Dunca - Stefan
Daciana Costina Andrada Dunca - Stefan
Visceral adiposity drives atherosclerosis and ectopic fat deposition, including hepatic steatosis, and is a major determinant of cardiometabolic risk in pediatric obesity. In adolescents, both BMI and WC are linked to cardiometabolic comorbidities, though their predictive accuracy differs. BMI is widely used due to its simplicity, low cost, and standardized reference values, but it cannot distinguish fat from lean mass, provides no information on fat distribution, and may misclassify children during rapid growth or puberty. Its association with metabolic risk also varies by sex, ethnicity, and developmental stage, limiting its value as a standalone indicator. Measures of central adiposity, including WC and waist-to-height ratio (WHtR), have gained increasing attention because they better capture visceral fat burden and show stronger associations with early metabolic dysfunction. Both WC and BMI are positively associated with elevated blood pressure and triglyceride concentrations and inversely associated with high-density lipoprotein cholesterol. Evidence shows that WC correlates more strongly than BMI with atherogenic lipid profiles, insulin resistance, alanine aminotransferase, and serum uric acid levels. Despite these advantages, the routine use of WC in pediatric practice is limited by the lack of standardized measurement protocols and universally accepted reference charts. Emerging evidence indicates that combining BMI and WC improves risk stratification compared with BMI alone. A two-step approach—using BMI for initial screening followed by WC or WHtR to assess central adiposity—may better identify high-risk children. Future research should integrate anthropometry with advanced imaging, molecular biomarkers, and AI-based models to enhance precision in cardiometabolic risk prediction.